

Follow-up of adults with noncritical COVID-19 two months after symptom onset

Claudia Carvalho-Schneider, Emeline Laurent, Adrien Lemaignen, Emilie Beaufils, Céline Bourbao-Tournois, Saïd Laribi, Thomas Flament, Nicole Ferreira-Maldent, Franck Bruyère, Karl Stefic, et al.

▶ To cite this version:

Claudia Carvalho-Schneider, Emeline Laurent, Adrien Lemaignen, Emilie Beaufils, Céline Bourbao-Tournois, et al.. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical Microbiology and Infection, 2021, 27 (2), pp.258-263. 10.1016/j.cmi.2020.09.052. hal-03282467

HAL Id: hal-03282467

https://hal.science/hal-03282467

Submitted on 9 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Follow-up of adults with non-critical COVID-19 two months after symptoms' onset

- 3 Claudia Carvalho-Schneider¹, Emeline Laurent^{2,3}, Adrien Lemaignen¹, Emilie Beaufils⁴,
- 4 Céline Bourbao-Tournois⁵, Saïd Laribi⁶, Thomas Flament⁷, Nicole Ferreira-Maldent⁸, Franck
- 5 Bruyère⁹, Karl Stefic^{10,11}, Catherine Gaudy-Graffin^{10,11}, Leslie Grammatico-Guillon^{2,11}, Louis
- 6 Bernard¹

1

2

- 8 ¹Service de Médecine Interne et Maladies Infectieuses (S2MI), Centre Hospitalier
- 9 Universitaire de Tours, 2 boulevard Tonnellé, 37000 Tours, France
- 10 ²Epidémiologie des Données cliniques en Centre-Val de Loire (*EpiDcliC*), Centre Hospitalier
- 11 Universitaire de Tours, 2 boulevard Tonnellé, 37000 Tours, France
- ³Equipe de recherche "Education Ethique Santé" (EE1 EES), université de Tours, 10
- boulevard Tonnellé, 37000 Tours, France
- ⁴ Centre Mémoire Ressources et Recherche (*CMRR*), Centre Hospitalier Universitaire de
- Tours, 2 boulevard Tonnellé, 37000 Tours, France
- ⁵Service de chirurgie digestive, Centre Hospitalier Universitaire de Tours, avenue de la
- 17 République, 37170 Chambray-lès-Tours, France
- 18 ⁶Service d'urgences et faculté de médecine, Centre Hospitalier Universitaire de Tours,
- 19 avenue de la République, 37170 Chambray-lès-Tours, France
- ⁷Service de pneumologie, Centre Hospitalier Universitaire de Tours, 2 boulevard Tonnellé,
- 21 37000 Tours, France
- 22 ⁸ Service de médecine interne, Centre Hospitalier Universitaire de Tours, 2 boulevard
- 23 Tonnellé, 37000 Tours, France
- ⁹ Service d'urologie, Centre Hospitalier Universitaire de Tours, 2 boulevard Tonnellé, 37000
- 25 Tours, France

¹⁰ Laboratoire de virologie, Centre Hospitalier Universitaire de Tours, 2 boulevard Tonnellé, 37000 Tours, France ¹¹Unité INSERM U1259, université de Tours, 10 boulevard Tonnellé, 37000 Tours, France Corresponding author: Dr Claudia Carvalho-Schneider, MD, Internal Medicine and Infectious Diseases Unit, 2 BdTonnellé, 37044 Tours, France C. CARVALHOS CHNEIDER@chu-tours.frTel +33-2-47-47-37-14, Fax: +33-2-47-47-37-31 **Abstract length**: 241 words

Paper length: 2,082 words

39 Abstract

- 40 Objectives
- 41 To describe the clinical evolution and predictors of symptom persistence during 2-month
- follow-up in adults with non-critical COVID-19.
- 43 *Methods*
- Descriptive clinical follow-up (days 7, 30 [D30] and 60 [D60]) of 150 patients with non-
- 45 critical COVID-19 confirmed by RT-PCR at Tours University Hospital from March 17 to
- 46 June 3, 2020, including demographic, clinical and laboratory data collected from the
- 47 electronic medical records and by phone call. Persisting symptoms were defined by the
- presence at D30 or D60 of at least one of the following: weight loss $\geq 5\%$, severe dyspnea or
- 49 asthenia, chest pain, palpitations, anosmia/ageusia, headache, cutaneous signs, arthralgia,
- 50 myalgia, digestive disorders, fever or sick leave.
- 51 Results
- 52 At D30, 68% (n=103/150) of patients presented at least one symptom and 66% (n=86/130) at
- 53 D60, mainly anosmia/ageusia: (59% (n=89/150) at symptom onset, 28% (n=40/150) at D30
- and 23% (n=29/130) at D60). Dyspnea concerned 36.7% (n=55/150) patients at D30 and 30%
- (n=39/130) at D60. Half of the patients (n=74/150) at D30 and 40% (n=52/130) at D60
- reported asthenia. Persistent symptoms at D60 were significantly associated with age 40 to 60
- 57 years old, hospital admission and abnormal auscultation at symptom onset. At D30, severe
- 58 COVID-19 and/or dyspnea at symptom onset were additional factors associated with
- 59 persistent symptoms.
- 60 Conclusions
- 61 Up to 2 months after symptom onset, two thirds of adults with non-critical COVID-19 had
- 62 complaints, mainly anosmia/ageusia, dyspnea or asthenia. A prolonged medical follow-up of
- patients with COVID-19 seems essential, whatever the initial clinical presentation.

Introduction

The most frequent symptoms of COVID-19 at disease onset are cough, fever, asthenia, myalgia, and altered smell or taste, including anosmia/ageusia. Respiratory distress can occur, mostly between 7 to 10 days after symptom onset (1–4). Recent studies investigating predictors of poor prognosis at an early stage identified potential risk factors for severe COVID-19 (1,5,6). One recent study in Italy by Carfi et al. described persistent symptoms after hospitalization for COVID-19 (7). Such evidence has not been reported for mild to moderate COVID-19. Our objective was to describe the clinical evolution and predictors of symptom persistence at D30 and D60 in patients with initial non-critical COVID-19. The aim was to highlight the initial key symptoms of COVID-19 to alert practitioners and patients of the risk of longer symptom duration in individuals with non-

Materials and methods

critical COVID-19.

78 Study design and population

This epidemiological study, based on a prospective follow-up, was carried out in our academic university hospital from March 17 to June 3, 2020. Inclusion criteria were: every adult patients (≥ 18 years old) with a confirmed diagnosis of COVID-19 (positive RT-PCR for SARS-CoV-2), and medical care in our hospital either in hospitalization or after consultation at the hospital's outpatient clinical evaluation center (OCEC). The OCEC has been developed to avoid consultation with the general practitioner (GP) or visit at the emergency department to reduce the risk of cross-transmission. The OCEC allowed 1) diagnosing COVID-19 by an RT-PCR test for SARS-CoV-2 with a nasopharyngeal swab; 2) assessing the risk of critical illness/deterioration and the need for surveillance; and 3) eventually proposing hospital admission to monitor the patient. Non-inclusion criteria were:

patients deceased or admitted to the ICU (considered as critical disease according to the WHO guidance for clinical management of COVID-19)(8), residents of retirement/nursery homes or long-term care facilities, patients transferred to another healthcare facility (i.e., other hospital, rehabilitation institution, retirement home), those unable to answer a phone questionnaire, and lost-to-follow-up patients at D30. The infectious diseases (ID) unit was in charge of the outpatient follow-up with confirmed COVID-19 but non-critical disease. Patients with or without clinical signs of pneumonia but without need for oxygen therapy were defined as having mild/moderate COVID-19. Patients with signs of pneumonia requiring oxygen therapy but not needing ICU admission were defined as having severe COVID-19, according to the WHO definition (8). The ID unit assessed these patients' clinical presentation at week one (day 7: D7), 1 month (day 30: D30) and 2 months (day 60: D60) after symptom onset by using a specific case report form (CRF) they developed. The phone interviews were conducted with a clinical decision algorithm to guide care advice messages, triage (evaluation of life-threatening conditions, especially at D7), and screening for COVID-19 symptom persistence or emergence. Baseline characteristics were retrospectively collected from patients' electronic medical records.

Outcome

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Persisting symptoms at D30 or D60 were defined as the presence of at least one of the following: weight loss $\geq 5\%$, grade 2-4 dyspnea according to the modified Medical Research Council (mMRC) scale(9), asthenia grade 3 or 4 according the World Health Organization (WHO) performance status classification(10), persisting chest pain, palpitations, anosmia/ageusia, headache, cutaneous signs (free description), arthralgia, myalgia, persisting digestive disorders (i.e. diarrhea, vomiting, pain), fever (>38°C temperature) or sick leave.

Data collection

- Demographic and initial clinical and laboratory data were collected from patients' electronic medical records (consultation or hospitalization). The relevant comorbidities were those considered at high risk for severe COVID-19 (i.e., obesity [body mass index > 30 kg/m²], chronic respiratory disease, dialysis, heart failure or previous cardiovascular event, liver cirrhosis, insulin-dependent diabetes, immunosuppression, pregnancy) (11).
- The follow-up information was collected by phone at D7, D30 and D60 with use of the specific standardized CRF:
 - Day 7, after symptom onset, by phone call for an outpatient or from the electronic medical record for an inpatient: dyspnea, fever, weight loss, chest pain, influenza-like symptoms (headache, asthenia, myalgia), digestive disorders (i.e., diarrhea, vomiting), anosmia and ageusia (supplementary material S1).
 - D30 and D60, after symptom onset, COVID-19 evolution was tracked by use of a specific standardized CRF (supplementary material S2) by phone call: persistence or emergence of sick leave, general condition (worse, same or better than before COVID-19), dyspnea using the mMRC scale, chest pain and triggering factor, palpitations, anosmia and ageusia on an analog scale (from 0, total anosmia/ageusia to 10, normal) at the worse moment of the disease and at 1-month follow-up, headache, asthenia (WHO), temperature >38°C, myalgia, arthralgia, digestive disorders (i.e., diarrhea, vomiting, pain) and cutaneous signs (supplementary material S2). Each symptom was considered only if not existing before the disease.

For a few clinical variables with a high proportion of missing data, physicians manually reviewed patient charts. Missing data concerned 0 to 29% of the data according to the variables at symptom onset, mainly for dyspnea, chest pain and abnormal auscultation. At

D30 and D60, there were few missing data, except for weight evolution (57% and 33% missing data at D30 and D60, respectively).

Statistical analyses

Descriptive statistics included frequency analyses (percentages) for categorical variables and mean (standard deviation [SD]) for quantitative variables. To identify predictors of clinical symptom persistence at D30 and D60, we used comparative analyses with chi-square test or Fisher test for categorical variables or Student *t* test or Mann-Whitney test for quantitative variables. On bivariate analysis, odds ratios along with their 95% confidence intervals (95% CIs) were calculated using logistic regression modelling. Analyses were done using SAS Enterprise Guide 71 64-bit (SAS Institute Inc., Cary, NC, USA). P< 0.05 was considered statistically significant. All tests were two-sided.

148 Ethics

All patients were informed of the potential reuse of their data for research purposes and could refuse to participate. This study was registered (no.2020_049) in the teaching hospital register of processing operations performed with personal data, as advised by the French authority *Commission Nationale de l'Informatique et des Libertés* (CNIL). We also had the approval of the local ethics committee in human research (no.2020_039).

Results

Over the first 6 weeks of the epidemic, 293 patients presented to our hospital, as in- or outpatients with RT-PCR-confirmed COVID-19. After excluding 64 ICU patients, 36 residents of nursery home or long-term facilities or patients transferred to another healthcare facility, 24 lost-to-follow-up at D30 and 19 deaths, we finally included 150 patients with non-

- 160 critical COVID-19 presentation. Between D30 and D60, 20 more patients were lost-to-
- 161 follow-up (Figure 1).
- The male/female ratio was 0.79 (females 56%, n=84/150); the mean age was 49 \pm 15 years.
- More than half of the patients (54%, n=80/150) had at least one comorbid condition and half
- were healthcare professionals (n=75/150). Despite the 20 patients lost-to-follow-up,
- demographic characteristics at D30 and D60 were similar (supplementary material S3).
- The most common symptoms at disease onset were flu-like symptoms (87%, n=129/150),
- anosmia/ageusia (59%, n=89/150) and fever (51%, n=76/150) (Table I).
- For the follow-up at D30 and D60, phone calls were performed at a mean of 32.7 ± 2.5 days
- (range 27 to 37) and 59.7 \pm 1.7 (range 57 to 67) after symptom onset. At D30, 103/150 (68%)
- patients reported at least one symptom as compared with 86/130 (66%) at D60 (Table II).
- However, each symptom was less frequently reported at D60 than D30, except for arthralgia.
- 172 At D30, 46% (n=73/150) of patients felt still sick or in a worse clinical condition than at
- 173 COVID-19 onset versus 37% (n=48/130) at D60.
- The most frequent symptom reported at D30 and D60 was anosmia/ageusia (Table I). On an
- analog scale (from 0, total anosmia/ageusia to 10, normal), at the worse moment of the
- disease, the mean anosmia and ageusia scores were 1.5 \pm 2.1 (range 0 to 8) and 1.9 \pm 2.5
- (range 0 to 8), respectively; at D30, the mean scores were 7 ± 2.9 (range 0 to 10) and 7.7 ± 1.00
- 178 2.3 (range 0 to 10); and at D60, they were 7.1 \pm 2.3 (range 0 to 10) and 8.3 \pm 1.6 (range 5 to
- 179 10), respectively.
- Persisting symptoms at D30 were significantly associated with hospital admission at
- symptom onset, initial clinical presentation, dyspnea and abnormal auscultation (Figure 2).
- Persisting clinical symptoms at D30 were associated with age class 40-60 years old but not
- pre-existing comorbid conditions. At D60, the associations remained for hospital admission
- and abnormal auscultation at symptom onset as well as the same age class 40-60 years old.

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

Discussion

This study showed that the medium-term course of 150 patients with mild or moderate COVID-19 was unfavorable: two-thirds of patients still reported symptoms at D30 and D60 and more than one-third felt still sick or in a worse clinical condition at D60 than at COVID-19 onset. These prolonged symptoms were significantly associated with age 40 to 60 years old, hospital admission at symptom onset, severe COVID-19, and dyspnea or abnormal auscultation. The main strength of our study was a well-documented prospective follow-up of patients with a non-critical COVID-19 presentation at the early stage and D30 and D60. Indeed, the recent international literature has provided evidence of the clinical presentation and evolution of COVID-19 patients(2,12-15) but mainly regarding the most severe cases in ICUs and predictors of the initial deterioration. The WHO has stated that median time from illness onset to recovery(16) is about 2 weeks for mild cases and 3 to 6 weeks with severe or critical disease. Small-scale studies in Wuhan, China showed that survivors continued to have poor lung and heart function (1). The initial clinical presentation for patients with mild or moderate COVID-19 (frequent respiratory and flu-like symptoms) was similar from previous studies (17,18) including patients with more severe clinical presentation at symptom onset described in New York, UK or Italy. However, the patients included in our study were younger (mean age 49, vs 62 to 73 years in severe cases) (13–15), and health professionals were overrepresented because of the national recommendations at this date and their prioritizing access to diagnostic tests (19). For patients with mild or moderate COVID-19, different symptoms such as anosmia/ageusia, myalgia or headache persisted. In a recent study, Lechien et al.(17) reported persistent olfactory dysfunction in 37.5% of patients at least 7 days after the end of mild to moderate COVID-19. The precise mechanism of this symptom is unknown. Patients should be informed of this anomaly and be referred to a specialist. In our study, at D30, half of the patients still felt sick or in a worse clinical condition than before symptom onset, and 7% reported severe asthenia (3.1% at D60). One-third of the patients had dyspnea and approximately one-sixth had chest pain. This situation is particularly frightening for patients. Rigorous studies with chest explorations seem necessary. Indeed, the evaluation at D30 and D60 was declarative over a phone call, without available physical, biological or imaging assessment. We controlled this potential reporting bias using standardized questionnaires administrated by trained investigators (supplementary data S1 and S2). However, subjective complaints are worth the attention and focus of the medical community and need to be taken into account in the medical care. Moreover, several infectious diseases such as primary cytomegalovirus or Epstein-Barr virus infection are known to be associated with persistent symptoms, without necessarily any obvious anomaly on physical examination (20–22). Heavy inflammatory response associated with symptomatic COVID-19 could promote such prolonged convalescence and persisting symptoms. Some authors also suggest the possibility of post-trauma stress disorder after COVID-19, which could contribute to a more prolonged experience of symptoms such asthenia or poor well-being (23,24). These complex tardive psychological disorders have already been shown after acute respiratory distress syndrome (25,26). This hypothesis could not be detailed in our study due to the lack of a reproducible psychological assessment, but should probably be explored. We found prolonged symptoms significantly associated in bivariate analysis with age 40 to 60 years old, hospital admission at symptom onset, severe COVID-19, and dyspnea or abnormal auscultation. As patients' baseline characteristics were partially retrospectively collected, data for potentially contributive factors were missing, preventing multivariate

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

modelling, as the main contributive factors in bivariate analysis (dyspnea, abnormal auscultation) had up to 29% of missing data. However, the findings of the bivariate analysis were clinically relevant. The smoking status was not available, it would have been interesting to look for an association with duration of symptoms (especially anosmia/ageusia or chronic dyspnea).

With this observational study allowing the prospective follow-up of 150 patients with non-critical COVID-19, we were able to assess the evolution of the disease and demonstrate that even the mildest presentation was associated with medium-term symptoms requiring follow-up. Thus, the COVID-19 pandemic will involve a care burden long after its end.

- 245 **Conflict of Interest Disclosures:** None reported.
- **Funding/Support:** We had no dedicated support for the research.
- 247 **Acknowledgments:** We thank all clinical and nursing staff who recruited and cared for the
- 248 patients at Tours University Hospital and staff (especially Léonard Bachellier, Côme Schmitt,
- 249 Marie Schneider, Anne-Sophie Lavedrine, Marie Leidlinger, Clotilde Laffitte, Gabrielle
- Valente, Amélie Gomez, Claire Corbillé, Camille Langbour, Marie Caroline Gabriel, Marion
- de Quillacq, Rémi Gervais, Sami El Meziani, Marie Fortin, Gaëlle Ragot, Julien Broustaille,
- 252 Dorian Gagnadoux, Eloise Bonnin, Léa Octrovée, Louise Huertas, Romuald Boivin,
- 253 Bérenger Le Roux, Nathalie Sayamath, Hortense Glérant) for logistics follow-up. We thank
- Laura Smales for English editing. None of these individuals received compensation for their
- role in the study.

256 Contribution:

- Conceptualization: Claudia Carvalho-Schneider, Louis Bernard, Emilie Beaufils
- Methodology: Emeline Laurent, Leslie Grammatico-Guillon
- Formal Analysis: Emeline Laurent, Leslie Grammatico-Guillon, Claudia Carvalho-
- Schneider Schneider
- Investigation: Claudia Carvalho-Schneider, Emilie Beaufils, Céline Bourbao-
- Tournois, Saïd Laribi, Thomas Flament, Nicole Ferreira-Maldent, Franck Bruyère,
- Adrien Lemaignen, Karl Stefic, Catherine Gaudy-Graffin
- Resources: Karl Stefic, Catherine Gaudy-Graffin
- 265 Data curation: Emeline Laurent, Leslie Grammatico-Guillon, Claudia Carvalho-
- Schneider Schneider
- Writing Original Draft: Claudia Carvalho-Schneider, Emeline Laurent, Louis
- Bernard, Adrien Lemaignen, Leslie Grammatico-Guillon
- Writing Review & Editing: Claudia Carvalho-Schneider, Emeline Laurent, Adrien
- Lemaignen, Emilie Beaufils, Céline Bourbao-Tournois, SaïdLaribi, Thomas Flament,

271		Nicole Ferreira-Maldent, Franck Bruyère, Karl Stefic, Catherine Gaudy-Graffin,
272		Leslie Grammatico-Guillon, Louis Bernard
273	-	Visualization: Claudia Carvalho-Schneider, Emeline Laurent, Louis Bernard, Adrien
274		Lemaignen, Leslie Grammatico-Guillon
275	-	Supervision: Louis Bernard, Claudia Carvalho-Schneider


276 References

- 277 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
- 278 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
- 279 study. Lancet Lond Engl. 28 2020;395(10229):1054-62.
- 280 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of
- 281 Coronavirus Disease 2019 in China. N Engl J Med. 30 2020;382(18):1708-20.
- 3. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in
- Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA.
- 284 22 avr 2020;
- 4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
- 286 with 2019 novel coronavirus in Wuhan, China. The Lancet. 15 févr 2020;395(10223):497
- 287 -506.
- 288 5. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early
- 289 Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19
- 290 Infection in Lombardy, Italy. J Clin Med. mai 2020;9(5):1548.
- 6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute
- Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019
- 293 Pneumonia in Wuhan, China. JAMA Intern Med. 13 mars 2020;
- 7. Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group.
- 295 Persistent Symptoms in Patients After Acute COVID-19. JAMA. 9 juill 2020;
- 8. Clinical management of COVID-19 [Internet]. [cité 6 août 2020]. Disponible sur:
- 297 https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19
- 9. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. Significance of Respiratory Symptoms
- and the Diagnosis of Chronic Bronchitis in a Working Population. Br Med J. 29 août
- 300 1959;2(5147):257-66.
- 301 10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity
- and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. déc
- 303 1982;5(6):649-55.
- 304 11. HCSP. Provisional statement: Recommendations on prevention and management of
- Covid-19 in patients at risk of severe forms [Internet]. Paris: Haut Conseil de la Santé
- 306 Publique; 2020 mars [cité 25 mai 2020]. Disponible sur:
- 307 https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=799
- 308 12. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical
- and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect
- 310 Dis. 27 mars 2020;

- 311 13. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
- Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to
- 313 ICUs of the Lombardy Region, Italy. JAMA. 06 2020;
- 314 14. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al.
- Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in
- New York City: a prospective cohort study. Lancet Lond Engl. 19 mai 2020;
- 317 15. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features
- of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical
- Characterisation Protocol: prospective observational cohort study. BMJ. 22 mai
- 320 2020;369:m1985.
- 321 16. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
- [Internet]. [cité 8 juin 2020]. Disponible sur: https://www.who.int/publications-detail-
- redirect/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
- 17. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al.
- 325 Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-
- moderate Coronavirus Disease 2019. J Intern Med. 30 avr 2020;
- 327 18. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
- tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 11 mai
- 329 2020;
- 330 19. HCSP. Provisional statement: Patients at risk of severe forms of Covid-19 and
- prioritising access to diagnostic tests [Internet]. Paris: Haut Conseil de la Santé Publique;
- 332 2020 mars [cité 17 juin 2020]. Disponible sur:
- 333 https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=798
- 20. Balfour HH, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, et al.
- A prospective clinical study of Epstein-Barr virus and host interactions during acute
- infectious mononucleosis. J Infect Dis. 1 nov 2005;192(9):1505-12.
- 337 21. Horwitz CA, Henle W, Henle G, Snover D, Rudnick H, Balfour HH, et al. Clinical and
- laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy
- individuals. Report of 82 cases. Medicine (Baltimore). mars 1986;65(2):124-34.
- 340 22. Wreghitt TG, Teare EL, Sule O, Devi R, Rice P. Cytomegalovirus infection in
- immunocompetent patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 déc
- 342 2003;37(12):1603-6.
- 343 23. Mahase E. Covid-19: What do we know about «long covid»? BMJ. 14
- 344 2020;370:m2815.
- 24. Xiao S, Luo D, Xiao Y. Survivors of COVID-19 are at high risk of posttraumatic stress
- disorder. Glob Health Res Policy. 2020;5:29.
- 25. Dutheil F, Mondillon L, Navel V. PTSD as the second tsunami of the SARS-Cov-2
- 348 pandemic. Psychol Med. 24 avr 2020;1-2.

26. Liu N, Zhang F, Wei C, Jia Y, Shang Z, Sun L, et al. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter.
 Psychiatry Res. 2020;287:112921.

354 Figure 1. Flow chart



*OCEC: outpatient clinical evaluation center

Table I. Patient symptoms at COVID-19 onset and at day 30 (D30) and 60 (D60).

	Onset n=150		D30 n=150			D60 =130
Fever (>38°C temperature)	76	(51.4)	5	(3.6)	0	(0.0)
Dyspnea/shortness of breath ¹	49	(42.2)	16	(10.7)	10	(7.7)
Chest pain	15	(14.0)	27	(18.0)	17	(13.1)
Abnormal auscultation	46	(39.3)	-		-	
Flu-like symptoms ²	129	(87.2)	54	(36.0)	28	(21.5)
Digestive disorders ³	48	(33.1)	26	(17.3)	15	(11.5)
Including diarrhea ⁴	44	(91.7)	13	(50.0)	5	(33.3)
Weight, mean ± SD	78.0 ± 19.4		77.2 ± 20.2		75.6 ± 18.0	
Weightloss ≥ 5%	-		13	(15.9)	15	(17.2)
Anosmia/ageusia	89	(59.3)	40	(27.8)	29	(22.7)
Palpitations	-		9	(6.5)	14	(10.9)
Arthralgia	-		13	(9.8)	21	(16.3)
Cutaneous signs	-		21	(15.4)	15	(11.5)
Initial hospitalization	53	(35.3)	-		-	·
Initial clinical presentation						
Mild/moderate COVID	116	(77.3)	-		-	
Severe COVID	34	(22.7)	-		-	
Sickleave	-		26	(19.7)	14	(11.2)

Data are n (%) unless indicated.

367

^{1:} grade 2-4 dyspnea according the modified Medical Research Council scale

^{2:} myalgia, headache and/or asthenia

^{3:} digestive disorders (i.e., diarrhea, vomiting)

^{4:} denominator is digestive disorders

Table II. Patient characteristics at days 30 (D30) and 60 (D60) after symptom onset for patients with ≥ 1 persisting symptom

	Total			≥1 persisting symptom at						
			D30 (n=150)			D60 (n = 130)				
	N	%	N	%	P value*	N	%	P value*		
Patients	150	100	103	68		86	66.1			
Female	84	56.0	59	57.3	0.6	48.0	55.8	0.3		
Age (years)					0.06			0.026		
<30	16	10.7	7	6.8		4	4.7			
30-39	32	21.3	21	20.4		19	22.1			
40-49	27	18.0	24	23.3		23	26.7			
50-59	37	24.7	28	27.2		21	24.4			
60-69	19	12.7	11	10.7		10	11.6			
≥70	19	12.7	12	11.7		9	10.5			
Healthcare professional	75	50.0	49	47.6	0.38	43.0	50.0	0.6		
Comorbid conditions (n) ¹					0.75			0.5		
0	69	46.0	46	45.6		42	48.8			
1	52	34.7	35	34.0		25	29.1			
2 or more	28	18.7	21	20.4		19	22.1			
Symptoms at onset										
Fever	76	51.4	54	53.5	0.45	44	52.4	0.8		
Dyspnea	49	42.2	38	50.0	0.02	28	45.2	0.3		
Chest pain	15	14.0	11	15.9	0.4	9	15.8	0.6		
Abnormal auscultation	46	39.3	38	47.5	0.0095	32	47.1	0.046		
Other respiratory signs ²	135	91.2	90	90.1	0.5	76	90.5	0.6		
Flu-like symptoms ³	129	87.2	88	87.1	0.99	73	86.9	0.7		
Diarrhea	44	30.8	31	32.0	0.65	26	32.5	1		
Anosmia/ageusia	89	59.3	63	61.2	0.5	55	64.0	0.2		
Initial hospitalization Initial clinical presentation	53	35.3	43		0.017 0.02	37	43	0.011 0.2		
Mild/moderate COVID	116	77.3	74	71.8		64	74.4			
Severe COVID	34	22.7	29	28.2		22	25.6			

^{*}compared to patients without persisting symptom

369

370


^{1:} i.e., obesity (body mass index > 30 kg/m²), chronic respiratory disease, dialysis, heart failure or previous cardiovascular event, liver cirrhosis, insulin-dependent diabetes, immunosuppression, pregnancy

^{2:} cough, sneeze and/or rhinitis


^{3:} myalgia, headache and/or asthenia

Figure 2.Predictors of persistent COVID-19 symptoms

Day 30



Day 60



378 **Supplementary material S1:**

379

380

COVID-19 phone follow-up (7 days) Demographic data: Name: First name: Onset of symptoms: Doctor: Date: Hospital discharge: Age: Profession: Medication: Yes No Questions Commentary Do you have shortness of breath? Do you have any fever (>38°C)? Do you have chills? Do you feel tired when you wake up? Do you have headache? Do you have chest pain? Do you have vomiting? Do you have diarrhea? Do you have myalgia? Do you cough? Do you have difficulty feeling the taste of food? Do you have a sense of smell? Does your nose run?

Supplementary material S2:

COVID-19 phone follow-up (days 30 and 60)								
Demographic data:								
Name:	First name:	Date:						
Questions								
Are you on sick leave?	Yes / No							
How do you evaluate your general	Worse than before COVID							
condition?	The same than before COVID							
	Better than before COVID							
Do you have shortness of breath?	Yes / No							
	If Yes: mMRC scale							
	Grade0: I onlygetbreathlesswithstrenuousexer	cise						
	Grade 1: I get short of breathwhenhurrying or	levelground or walking up						
	a slighthill							
	Grade 2: On levelground, I walkslowerthan po							
	sameagebecause of breathlessness, or I have to							
	breathwhenwalking at myown pace on the lev							
	Grade 3: I stop for breathafterwalking about 1	00 yards or aftera few						
	minutes on levelground							
	Grade 4: I amtoobreathless to leave the house	or I ambreathlesswhen						
D 1 6 (2000)	dressing							
Do you have fever (>38°C)?	Yes / No							
	If Yes: new / persistant							
Do you have persistent abnormal fatigue?	Yes/No							
	If Yes: WHO performance status classification							
	0: able to carry out all normal activity without restriction							
	1: restricted in strenuous activity but ambulatory and able to carry out light work							
	2: ambulatory and capable of all self-care but unable to carry out any							
	work activities; up and about more than 50% of waking hours							
	3: symptomatic and in a chair or in bed for greater than 50% of the day							
	but not bedridden							
	4: completely disabled; cannot carry out any self-care; totally confined to							
	bed or chair.							
Do you have headache?	Yes / No							
Do you have chest pain?	Yes / No							
	If Yes: Trigger: inspiration / cough / effort / r	none						
Do you have digestive disorders?	Yes / No							
	If Yes: diarrhea / vomiting / abdominal pain							
Do you have myalgia?	Yes / No							
Do you or did you have arthralgia?	Never / Yes, disappeared / Yes, persistent / Ye	es, appeared						
Do you or did you have difficulty feeling Yes / No								
the taste of food?	If Yes:							
	Use analog scale (from 0, total taste loss to 10	normal) at the worse						
	moment of the disease and today							
Do you or did you have a loss of smell?								
	If Yes:							
	Use analog scale (from 0, total smell loss to 1	U,normal) at the worse						
D 111 1 1 1 2 2	moment of the disease and today	1						
Do you or did you have palpitations?	Never / Yes, disappeared / Yes, persistent / Yes							
Do you or did you have cutaneous signs?	Never / Yes, disappeared / Yes, persistent / Yes	es, appeared						

384 Supplementary material S3: Characteristics of the 20 patients lost to follow-up at D60

				D60		
	follow-up		-	lost to f	ollow-up	
	n=130			n = 20		p-value
Female	68	52.3		16	80.0	0.02
Age (years)						0.44
<30	12	9.2		4	20.0	
30-39	28	21.5		4	20.0	
40-49	26	20.0		1	5.0	
50-59	31	23.8		6	30.0	
60-69	17	13.1		2	10.0	
≥70	16	12.3		3	15.0	
Healthcare professional	67	51.5		8	40.0	0.34
Comorbid conditions (n) ¹						0.07
0	64	49.2		5	26.3	
1	41	31.5		11	57.9	
2 or more	25	19.2		3	15.8	
Symptoms at onset						
Fever	66	51.6		10	50.0	0.90
Dyspnea	40	40.8		9	50.0	0.47
Chest pain	13	14.3		2	12.5	1.00
Abnormal auscultation	41	40.2		5	33.3	0.61
Other respiratory signs ²	117	91.4		18	90.0	0.69
Flu-like symptoms ³	110	85.9		19	95.0	0.47
Diarrhea	40	32.5		4	20.0	0.26
Anosmia/ageusia	78	60.0		11	55.0	0.67
Initial hospitalization	46	35.4		7	35.0	0.97
Initial clinical presentation						0.78
Mild/moderate COVID	101	77.7		15	75.0	
Severe COVID	29	22.3		5	25.0	

^{1:} i.e., obesity (body mass index > 30 kg/m²), chronic respiratory disease, dialysis, heart failure or previous cardiovascular event, liver cirrhosis, insulin-dependent diabetes, immunosuppression, pregnancy

385

386

387

^{388 2:} cough, sneeze and/or rhinitis

^{3:} myalgia, headache and/or asthenia